Brain damage in preterm newborns: Biological response modifications as a strategy to reduce disabilities

Journal of Pediatrics

Volumn 136, Issue 4, 2000, Pages 433-438

  Dammann, Olaf ^a   Leviton, Alan ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BIOLOGICAL RESPONSE MODIFIER; CASPASE; CYTOKINE; CYTOKINE RECEPTOR; DIZOCILPINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NEUTRALIZING ANTIBODY; PADGEM PROTEIN;

ARTICLE; BRAIN INJURY; DISABILITY; FETUS; HUMAN; INFECTION; NEUROPROTECTION; NEWBORN; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0033914782     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(00)90004-0     Document Type: Article

References (75)

1. 1. Escobar GJ, Littenberg B, Petitti DB. Outcome among surviving very low birthweight infants: a meta-analysis. Arch Dis Child 1991;66:204-11.
2. 2. Tin W, Wariyar U, Hey D. Changing prognosis for babies of less than 28 weeks' gestation in the north of England between 1983 and 1994. BMJ 1997;314:107-11.
3. 3. Hall A, McLeod A, Counsell C, Thomson L, Mutch L. School attainment, cognitive ability and motor function in a total Scottish very-low-birthweight population at eight years: a controlled study. Dev Med Child Neurol 1995; 37:1037-50.
4. 4. Schothorst PF, van Engeland H. Long-term behavioral sequelae of prematurity. J Am Acad Child Adolesc Psychiatry 1996;35:175-83.
5. 5. McCarton CM, Brooks-Gunn J, Wallace IF, Bauer CR, Bennett FC, Bernbaum JC, et al. Results at age 8 years of early intervention for low-birth-weight premature infants. The Infant Health and Development Program. JAMA 1997;277:126-32.
6. 6. Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early Hum Dev 1999;53:193-218.
7. 7. Dammann O, Leviton A. The role of perinatal brain damage in developmental disabilities: an epidemiologic perspective. Ment Retard Dev Disabil Res Rev 1997;3:13-21.
8. 8. Whitaker AH, Feldman JF, Van Rossem R, Schonfeld IS, Pinto-Martin JA, Torre C, et al. Neonatal cranial ultrasound abnormalities in low birth weight infants: relation to cognitive outcomes at six years of age. Pediatrics 1996;98:719-29.
9. 9. Whitaker AH, Van Rossem R, Feldman JF, Schonfeld IS, Pinto-Martin JA, Tore C, et al. Psychiatric outcomes in low-birth-weight children at age 6 years: relation to neonatal cranial ultrasound abnormalities. Arch Gen Psychiatry 1997;54:847-56.
10. 10. Dammann O, Leviton A. Brain damage in preterm newborns: Might enhancement of developmentally-regulated endogenous protection open a door for prevention? Pediatrics 1999;104:541-50.
11. 11. Adinolfi M. Infectious diseases in pregnancy, cytokines and neurological impairment: an hypothesis. Dev Med Child Neurol 1993;35:549-53.
12. 12. Leviton A. Preterm birth and cerebral palsy: Is tumor necrosis factor the missing link? Dev Med Child Neurol 1993;35:553-8.
13. 13. Atici A, Satar M, Alparslan N. Serum interleukin-1beta in neonatal sepsis. Acta Paediatr 1996;85:371-4.
14. 14. Berner R, Niemeyer CM, Leititis JU, Funke A, Schwab C, Rau U, et al. Plasma levels and gene expression of granulocyte colony-stimulating factor, tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, IL-8, and soluble intercellular adhesion molecule-1 in neonatal early onset sepsis. Pediatr Res 1998;44:469-77.
15. 15. Andrews WW, Goldenberg RL, Hauth JC. Preterm labor: emerging role of genital tract infections. Infect Agents Dis 1995;4:196-211.
16. 16. Kundsin RB, Leviton A, Allred EN, Poulin SA. Ureaplasma urealyticum infection of the placenta in pregnancies that ended prematurely. Obstet Gynecol 1996;87:122-7.
17. 17. Newton ER, Piper J, Peairs W. Bacterial vaginosis and intraamniotic infection. Am J Obstet Gynecol 1997;176: 672-7.
18. 18. Dammann O, Leviton A. The role of the fetus in perinatal infection and neonatal brain injury. Curr Opin Pediatr 2000. In press.
19. 19. Romero R, Gomez R, Ghezzi F, Yoon BH, Mazor M, Edwin SS, et al. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. Am J Obstet Gynecol 1998;179:186-93.
20. 20. Yoon BH, Romero R, Yang SH, Jun JK, Kim IO, Choi JH, et al. Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. Am J Obstet Gynecol 1996;174:1433-40.
21. 21. Leviton A, Paneth N, Reuss ML, Susser M, Allred EN, Dammann O, et al. Maternal infection, fetal inflammatory response, and brain damage in very low birthweight infants. Pediatr Res 1999;46;566-75.
22. 22. Adinolfi M. The development of the human blood-CSF-brain barrier. Dev Med Child Neurol 1985;27:532-7.
23. 23. Megyeri P, Abraham CS, Temesvari P, Kovacs J, Vas T, Speer CP. Recombinant human tumor necrosis factor alpha constricts pial arterioles and increases blood-brain barrier permeability in newborn piglets. Neurosci Lett 1992;148:137-40.
24. 24. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997;42:1-8.
25. 25. Deguchi K, Mizuguchi M, Takashima S. Immunohistochemicai expression of tumor necrosis factor alpha in neonatal leukomalacia. Pediatr Neurol 1996;14: 13-6.
26. 26. Deguchi K, Oguchi K, Takashima S. Characteristic neuropathology of leukomalacia in extremely low birth weight infants. Pediatr Neurol 1997; 16:296-300.
27. 27. Yoon BH, Romero R, Kim CJ, Koo JN, Choe G, Syn HC, et al. High expression of tumor necrosis factor-alpha and interleukin-6 in periventricular leukomalacia. Am J Obstet Gynecol 1997;177:406-11.
28. 28. Dammann O, Leviton A. Infection remote from the brain, neonatal white matter damage, and cerebral palsy in the preterm infant. Semin Pediatr Neurol 1998;5:190-201.
29. 29. Yoon BH, Kim CJ, Romero R, Jun JK, Park KH, Choi ST, et al. Experimentally induced intrauterine infection causes fetal brain white matter lesions in rabbits. Am J Obstet Gynecol 1997; 177:797-802.
30. 30. Debillon T, Gras-Leguen C, Verielle V, Winer N, Caillon J, Roze JC, et al. Intrauterine infection induces periventricular white matter cell death in rabbits. Pediatr Res 2000. In press.
31. 31. Gilles FH, Leviton A, Kerr CS. Endotoxin leucoencephalopathy in the telencephalon of the newborn kitten. J Neurol Sci 1976;27:183-91.
32. 32. Gilles FH, Averill DRJ, Kerr CS. Neonatal endotoxin encephalopathy. Ann Neurol 1977;2:49-56.
33. 33. Hagberg H, Eklind S, Hallin U, Puka-Sundvall M, Andersson AL, Bona E, et al. Expression of cytokines and chemokines in the immature white and gray matter in response to hypoxia-ischemia or endotoxin [abstract]. J Cereb Blood Flow Metab 1999;19 (Suppl 1):S312.
34. 33a. Cai Z, Pan ZL, Pang Y, Evans OB, Rhodes PG. Cytokine induction in fetal rats after maternal lipopolysaccharide administration. Pediatr Res 2000;47:64-72.
35. 34. Fellman V, Raivio KO. Reperfusion injury as the mechanism of brain damage after perinatal asphyxia. Pediatr Res 1997;41:599-606.
36. 35. Silverstein FS, Barks JDE, Hagan P, Liu XH, Ivacko J, Szaflarski J. Cytokines and perinatal brain injury. Neurochem Int 1997;30:375-83.
37. 36. du Plessis AJ, Johnston MV. Hypoxic-ischemic brain injury in the newborn. Cellular mechanisms and potential strategies for neuroprotection. Clin Perinatol 1997;24:627-54.
38. 37. Nicotera P, Lipton SA. Excitotoxins in neuronal apoptosis and necrosis. J Cereb Blood Flow Metab 1999;19:583-91.
39. 38. Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ. Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J Neurosci 1993;13:1441-53.
40. 39. Szaflarski J, Burtrum D, Silverstein FS. Cerebral hypoxia-ischemia stimulates cytokine gene expression in perinatal rats. Stroke 1995;26:1093-100.
41. 40. Bona E, Andersson AL, Blomgren K, Gilland E, Puka-Sundvall M, Gustalson K, et al. Chemokine and inflammatory cell response to hypoxia-ischemia in immature rats. Pediatr Res 1999;45:500-9.
42. 41. Loddick SA, Rothwell NJ. Commentary. Mechanisms of tumor necrosis factor alpha action on neurodegeneration: interactions with insulin-like growth factor-1. Proc Natl Acad Sci USA 1999;96:9449-51.
43. 42. Cheng B, Christakos S, Mattson MR. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Neuron 1994;12:139-53.
44. 43. Chao CC, Hu S. Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. Dev Neurosci 1994;16:172-9.
45. 44. Kuban KC. White-matter disease of prematurity, periventricular leukomalacia, and ischemic lesions. Dev Med Child Neurol 1998;40:571-3.
46. 45. Sävman K, Blennow M, Gustafson K, Tarkowski E, Hagberg H. Cytokine response in cerebrospinal fluid after birth asphyxia. Pediatr Res 1998;43: 746-51.
47. 46. Dammann O, Durum SK, Leviton A. Modification of the infection-associated risks of preterm birth and white matter damage in the preterm newborn by polymorphisms in the tumor necrosis factor-locus? Pathogenesis 1999;1:171-7.
48. 47. Loddick SA, Wong ML, Bongiorno PB, Gold PW, Licinio J, Rothwell NJ. Endogenous interleukln-1 receptor antagonist is neuroprotective. Biochem Biophys Res Commun 1997;234:211-5.
49. 48. Hagberg H, Gilland E, Bona E, Hanson L, Hann-Zoric M, Blennow M, et al. Enhanced expression of interleukin (IL)-1 and 1L-6 messenger RNA and bioactive protein after hypoxia-ischemia in neonatal rats. Pediatr Res 1996;40:603-9.
50. 49. Eriksson C, Winblad B, Schultzberg M. Kainic acid induced expression of interleukin-1 receptor antagonist mRNA in the rat brain. Brain Res Mol Brain Res 1998;58:195-208.
51. 50. Yang GY, Zhao YJ, Davidson BL, Betz AL. Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury. Brain Res 1997;751:181-8.
52. 51. Relton JK, Martin D, Thompson RC, Russell DA. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 1996; 138:206-13.
53. 52. Gong C, Qin Z, Betz AL, Liu XH, Yang GY. Cellular localization of tumor necrosis factor alpha following focal cerebral ischemia in mice. Brain Res 1998;801:1-8.
54. 53. Yang GY, Gong C, Qin Z, Ye W, Mao Y, Bertz AL. Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport 1998;9:2131-4.
55. 54. Yang GY, Gong C, Qin Z, Liu XH, Lorris Betz A. Tumor necrosis factor alpha expression produces increased blood-brain barrier permeability following temporary focal cerebral ischemia in mice. Brain Res Mol Brain Res 1999;69:135-43.
56. 55. Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, et al. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 1997;94:2007-12.
57. 56. Cheng Y, Deshmukh M, D'Costa A, Demaro JA, Gidday JM, Shah A, et al. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest 1998;101:1992-9.
58. 57. Silverstein FS. Can inhibition of apoptosis rescue ischemic brain? J Clin Invest 1998;101:1809-10.
59. 58. Zhang RL, Chopp M, Li Y, Zaloga C, Jiang N, Jones ML, et al. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 1994;44:1747-51.
60. 59. Stanimirovic D, Shapiro A, Wong J, Hutchison J, Durkin J. The induction of ICAM-1 in human cerebromicrovascular endothelial cells (HCEC) by ischemia-like conditions promotes enhanced neutrophil/HCEC adhesion. J Neuroimmunol 1997;76:193-205.
61. 60. Kyrkanides S, Olschowka JA, Williams JP, Hansen JT, O'Banion MK. TNF alpha and IL-1beta mediate intercellular adhesion molecule-1 induction via microglia-astrocyte interaction in CNS radiation injury. J Neuroimmunol 1999;95:95-106.
62. 61. Yang GY, Mao Y, Zhou LF, Gong C, Ge HL, Betz AL. Expression of intercellular adhesion molecule 1 (ICAM-1) is reduced in permanent focal cerebral ischemic mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist. Brain Res Mol Brain Res 1999;65:143-50.
63. 62. Goussev AV, Zhang Z, Anderson DC, Chopp M. P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat. Neurol Sci 1998;161:16-22.
64. 63. Suzuki H, Hayashi T, Tojo SJ, Kitagawa H, Kimura K, Mizugaki M, et al. Anti-P-selectin antibody attenuates rat brain ischemic injury. Neurosci Lett 1999;265:163-6.
65. 64. Suzuki H, Abe K, Tojo SJ, Kitagawa H, Kimura K, Mizugaki M, et al. Reduction of ischemic brain injury by anti-P-selectin monoclonal antibody after permanent middle cerebral artery occlusion in rat. Neurol Res 1999;21: 269-76.
66. 65. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 1998;251:189-92.
67. 66. Herberman RB. Cancer therapy by biological response modifiers. Arzneimittelforschung 1987;37(2A):246-50.
68. 67. O'Connor TE, West WH, Marshall GD, Orr DW, Lewis M, Oldham RK. Principles of biotherapy and its application to the treatment of disseminated renal cancer. Semin Surg Oncol 1988; 4:155-60.
69. 68. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999;21:75-87.
70. 69. Bansil S, Cook SD, Rohowsky-Kochan C. Multiple sclerosis: immune mechanisms and update on current therapies. Ann Neurol 1995;37(S1): S87-S101.
71. 70. Munschauer FER, Stuart WH. Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis. Clin Ther 1997;19:868-82.
72. 71. Graves DT. The use of biologic response modifiers in human clinical trials. Ann Periodontol 1997;2:259-67.
73. 72. Keystone EC. The role of tumor necrosis factor antagonism in clinical practice. J Rheumatol 1999;26(Suppl 57): 22-8.
74. 73. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
75. 74. Cotman CW, Hailer NP, Pfister KK, Soltesz I, Schachner M. Cell adhesion molecules in neural plasticity and pathology: Similar mechanisms, distinct organizations? Prog Neurobiol 1998;55:659-69.